Skip to main content

Table 4 Risk factors associated with 14-day and 30-day mortality in patients with MRSA bacteremia

From: Evaluation of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Epidemiology, clinical characteristics, and outcomes in the older patients in a tertiary teaching hospital in Malaysia

Risk factors

Adjusted Odds Ratio with 95% Confidence Interval

14-day Mortality

p-value

30-day Mortality

p-value

Age ≥ 65 years

3.19 (0.89–11.50)

0.311

3.36 (1.24–9.13)

0.024*

Pitt score ≥ 3

2.11 (1.52–2.93)

< 0.001*

2.15 (1.54–3.01)

< 0.001*

Charlson score > 4

1.06 (0.87–1.30)

0.298

1.03 (0.87–1.22)

0.752

Chronic kidney disease

0.83 (0.25–2.74)

0.371

2.45 (0.91–6.59)

0.150

Diabetes mellitus

1.89 (0.62–5.79)

0.282

1.91 (0.74–4.92)

0.226

Indwelling urinary catheters

2.11 (0.37–12.05)

< 0.001*

5.43 (1.39–21.23)

< 0.001*

No infectious disease team consult

6.38 (1.96–20.72)

< 0.001*

2.90 (1.04–8.11)

0.032*

Previous exposure to antibiotics

2.87 (0.64–12.79)

0.351

2.04 (0.67–6.27)

0.168

Non-effective empirical therapy

1.46 (0.35–5.62)

0.824

1.90 (0.52–6.89)

0.828

Hospital-acquired MRSA

7.05 (1.61–30.85)

0.021*

6.12 (1.81–20.72)

0.017*

Healthcare-associated MRSA

3.03 (0.95–9.64)

0.463

3.19 (1.30–7.81)

0.043*

Hypoalbuminemia (< 29 g/L)

1.66 (0.51–5.42)

0.386

3.31 (1.25–8.79)

0.017*

Polymicrobial bacteremia

3.35 (0.43–1.07)

0.032*

2.50 (0.95–6.58)

0.282

Inappropriate targeted treatment

3.38 (0.54–21.19)

0.694

8.08 (1.15–56.86)

0.024*

Inappropriate treatment duration

1.49 (0.48–4.65)

0.160

1.62 (0.61–4.32)

0.410

  1. *p-value < 0.05 indicates statistical significance